{
    "info": {
        "nct_id": "NCT06501196",
        "official_title": "A Phase 1/1b Open-Label, Dose Escalation, First-in- Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-leukemic Activity of the Orally Available CDC-Like Kinase (CLK) Inhibitor, BH-30236, in Adults With Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML) or Higher-Risk Myelodysplastic Syndrome (HR-MDS)",
        "inclusion_criteria": "Healthy volunteers allowed\nMust have minimum age of 18 Years",
        "exclusion_criteria": "* Diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia with blast crisis.\n* Prior allogeneic HSCT within 3 months or donor lymphocyte infusion within 30 days of start of therapy;\n* Active and uncontrolled infections.\n* Unresolved AEs greater than Grade from prior therapies.\n* History of other active malignancy (with certain exceptions)\n* Prior treatment with a CLK inhibitor.\n* Any acute or chronic graft versus host disease requiring systemic therapy within 4 weeks prior to study drug administration with the exception of topical steroids or the equivalent of 20 mg of prednisone or less.\n\nThe above is a summary, other exclusion criteria details may apply.",
        "miscellaneous_criteria": "Inclusion criteria:\n\n* ≥18 years.\n* Diagnosis of relapsed/refractory acute myelogenous leukemia (R/R) AML or higher-risk myelodysplastic syndrome (HR-MDS) with ≥5% bone marrow blast at time of inclusion.\n* Prior treatment history must include 1-5 prior lines of therapy.\n* ECOG performance status ≤2.\n* Adequate organ function evidenced by the following laboratory values:\n* Hepatic: Transaminase levels aspartate aminotransferase [AST]/ alanine transaminase [ALT] ≤ 2.5 × upper limit of normal (ULN). In cases of liver involvement by AML or MDS, AST and ALT < 5.0 × ULN is acceptable. Total bilirubin ≤ 1.5 × ULN in the absence of documented Gilbert's disease.\n* Renal: Measured or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula)\n\nThe above are a summary, other inclusion criteria details may apply."
    },
    "inclusion_lines": [
        {
            "line": "Healthy volunteers allowed",
            "criterions": [
                {
                    "exact_snippets": "Healthy volunteers allowed",
                    "criterion": "healthy volunteer status",
                    "requirements": [
                        {
                            "requirement_type": "eligibility",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "Must have minimum age of 18 Years",
            "criterions": [
                {
                    "exact_snippets": "minimum age of 18 Years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "Years"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "exclusion_lines": [
        {
            "line": "The above is a summary, other exclusion criteria details may apply.",
            "criterions": [
                {
                    "exact_snippets": "other exclusion criteria details may apply",
                    "criterion": "other exclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment with a CLK inhibitor.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment with a CLK inhibitor.",
                    "criterion": "prior treatment with a CLK inhibitor",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Active and uncontrolled infections.",
            "criterions": [
                {
                    "exact_snippets": "Active and uncontrolled infections",
                    "criterion": "infections",
                    "requirements": [
                        {
                            "requirement_type": "activity",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "control_status",
                            "expected_value": "uncontrolled"
                        }
                    ]
                }
            ]
        },
        {
            "line": "* History of other active malignancy (with certain exceptions)",
            "criterions": [
                {
                    "exact_snippets": "History of other active malignancy (with certain exceptions)",
                    "criterion": "other active malignancy",
                    "requirements": [
                        {
                            "requirement_type": "history",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "activity status",
                            "expected_value": "active"
                        },
                        {
                            "requirement_type": "exclusion",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Unresolved AEs greater than Grade from prior therapies.",
            "criterions": [
                {
                    "exact_snippets": "Unresolved AEs greater than Grade from prior therapies.",
                    "criterion": "adverse events from prior therapies",
                    "requirements": [
                        {
                            "requirement_type": "resolution status",
                            "expected_value": "unresolved"
                        },
                        {
                            "requirement_type": "severity grade",
                            "expected_value": {
                                "operator": ">",
                                "value": 1,
                                "unit": "Grade"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Any acute or chronic graft versus host disease requiring systemic therapy within 4 weeks prior to study drug administration with the exception of topical steroids or the equivalent of 20 mg of prednisone or less.",
            "criterions": [
                {
                    "exact_snippets": "Any acute or chronic graft versus host disease requiring systemic therapy within 4 weeks prior to study drug administration",
                    "criterion": "graft versus host disease (GVHD) requiring systemic therapy",
                    "requirements": [
                        {
                            "requirement_type": "presence",
                            "expected_value": false
                        },
                        {
                            "requirement_type": "time window",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 4,
                                        "unit": "weeks prior to study drug administration"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "with the exception of topical steroids or the equivalent of 20 mg of prednisone or less",
                    "criterion": "systemic therapy for GVHD",
                    "requirements": [
                        {
                            "requirement_type": "type of therapy",
                            "expected_value": [
                                "topical steroids",
                                "prednisone ≤ 20 mg or equivalent"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Diagnosis of acute promyelocytic leukemia or chronic myeloid leukemia with blast crisis.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of acute promyelocytic leukemia",
                    "criterion": "acute promyelocytic leukemia",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                },
                {
                    "exact_snippets": "Diagnosis of ... chronic myeloid leukemia with blast crisis",
                    "criterion": "chronic myeloid leukemia with blast crisis",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "miscellaneous_lines": [
        {
            "line": "* Diagnosis of relapsed/refractory acute myelogenous leukemia (R/R) AML or higher-risk myelodysplastic syndrome (HR-MDS) with ≥5% bone marrow blast at time of inclusion.",
            "criterions": [
                {
                    "exact_snippets": "Diagnosis of relapsed/refractory acute myelogenous leukemia (R/R) AML",
                    "criterion": "acute myelogenous leukemia (AML)",
                    "requirements": [
                        {
                            "requirement_type": "diagnosis",
                            "expected_value": true
                        },
                        {
                            "requirement_type": "disease status",
                            "expected_value": [
                                "relapsed",
                                "refractory"
                            ]
                        }
                    ]
                },
                {
                    "exact_snippets": "higher-risk myelodysplastic syndrome (HR-MDS)",
                    "criterion": "myelodysplastic syndrome (MDS)",
                    "requirements": [
                        {
                            "requirement_type": "risk category",
                            "expected_value": "higher-risk"
                        }
                    ]
                },
                {
                    "exact_snippets": "≥5% bone marrow blast at time of inclusion",
                    "criterion": "bone marrow blast percentage",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 5,
                                "unit": "%"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Adequate organ function evidenced by the following laboratory values:",
            "criterions": [
                {
                    "exact_snippets": "Adequate organ function",
                    "criterion": "organ function",
                    "requirements": [
                        {
                            "requirement_type": "adequacy",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "The above are a summary, other inclusion criteria details may apply.",
            "criterions": [
                {
                    "exact_snippets": "other inclusion criteria details may apply",
                    "criterion": "other inclusion criteria",
                    "requirements": [
                        {
                            "requirement_type": "applicability",
                            "expected_value": true
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ≥18 years.",
            "criterions": [
                {
                    "exact_snippets": "≥18 years",
                    "criterion": "age",
                    "requirements": [
                        {
                            "requirement_type": "minimum value",
                            "expected_value": {
                                "operator": ">=",
                                "value": 18,
                                "unit": "years"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Renal: Measured or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula)",
            "criterions": [
                {
                    "exact_snippets": "Measured or calculated creatinine clearance ≥ 60 mL/min (Cockcroft-Gault formula)",
                    "criterion": "creatinine clearance",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "operator": ">=",
                                "value": 60,
                                "unit": "mL/min"
                            }
                        },
                        {
                            "requirement_type": "measurement_method",
                            "expected_value": [
                                "measured",
                                "calculated (Cockcroft-Gault formula)"
                            ]
                        }
                    ]
                }
            ]
        },
        {
            "line": "* ECOG performance status ≤2.",
            "criterions": [
                {
                    "exact_snippets": "ECOG performance status ≤2",
                    "criterion": "ECOG performance status",
                    "requirements": [
                        {
                            "requirement_type": "score",
                            "expected_value": {
                                "operator": "<=",
                                "value": 2,
                                "unit": "N/A"
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Prior treatment history must include 1-5 prior lines of therapy.",
            "criterions": [
                {
                    "exact_snippets": "Prior treatment history must include 1-5 prior lines of therapy.",
                    "criterion": "prior lines of therapy",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": ">=",
                                        "value": 1,
                                        "unit": "lines"
                                    },
                                    {
                                        "operator": "<=",
                                        "value": 5,
                                        "unit": "lines"
                                    }
                                ]
                            }
                        }
                    ]
                }
            ]
        },
        {
            "line": "* Hepatic: Transaminase levels aspartate aminotransferase [AST]/ alanine transaminase [ALT] ≤ 2.5 × upper limit of normal (ULN). In cases of liver involvement by AML or MDS, AST and ALT < 5.0 × ULN is acceptable. Total bilirubin ≤ 1.5 × ULN in the absence of documented Gilbert's disease.",
            "criterions": [
                {
                    "exact_snippets": "Transaminase levels aspartate aminotransferase [AST]/ alanine transaminase [ALT] ≤ 2.5 × upper limit of normal (ULN). In cases of liver involvement by AML or MDS, AST and ALT < 5.0 × ULN is acceptable.",
                    "criterion": "aspartate aminotransferase (AST) and alanine transaminase (ALT) levels",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 2.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "quantity (with liver involvement by AML or MDS)",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<",
                                        "value": 5.0,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "Total bilirubin ≤ 1.5 × ULN in the absence of documented Gilbert's disease.",
                    "criterion": "total bilirubin",
                    "requirements": [
                        {
                            "requirement_type": "quantity",
                            "expected_value": {
                                "comparisons": [
                                    {
                                        "operator": "<=",
                                        "value": 1.5,
                                        "unit": "ULN"
                                    }
                                ]
                            }
                        },
                        {
                            "requirement_type": "absence of documented Gilbert's disease",
                            "expected_value": true
                        }
                    ]
                }
            ]
        }
    ],
    "failed_inclusion": [],
    "failed_exclusion": [
        {
            "line": "* Prior allogeneic HSCT within 3 months or donor lymphocyte infusion within 30 days of start of therapy;",
            "criterions": [
                {
                    "exact_snippets": "Prior allogeneic HSCT within 3 months of start of therapy",
                    "criterion": "prior allogeneic HSCT",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 3,
                                "unit": "months"
                            }
                        }
                    ]
                },
                {
                    "exact_snippets": "donor lymphocyte infusion within 30 days of start of therapy",
                    "criterion": "donor lymphocyte infusion",
                    "requirements": [
                        {
                            "requirement_type": "time since procedure",
                            "expected_value": {
                                "operator": "<=",
                                "value": 30,
                                "unit": "days"
                            }
                        }
                    ]
                }
            ]
        }
    ],
    "failed_miscellaneous": [
        {
            "line": "Inclusion criteria:",
            "criterions": []
        }
    ]
}